10 Oct UW–Madison to lead nation in boron neutron capture therapy for cancer
Alphabeam compact accelerator-based BNCT system
The University of Wisconsin–Madison and TAE Life Sciences, a biotechnology company specializing in targeted radiation therapy for cancer care, have signed a memorandum of understanding, or MOU, announcing the intention to launch the first accelerator-based boron neutron capture therapy (BNCT) center in the United States.
As part of this collaboration, the University of Wisconsin School of Medicine and Public Health would install the Alphabeam compact accelerator-based BNCT system developed by TAE Life Sciences. This significant milestone has the potential to pave the way for the adoption of BNCT in the United States.
The proposal involves collaboration on research and development of Alphabeam and novel boron-10 drugs through pre-clinical and clinical studies on several cancer indications with high unmet need, including brain and head and neck cancers.
We aim to revolutionize the landscape for cancer treatment, and make even the most challenging cancers treatable with minimal side effects. – Robert Hill, CEO, TAE Life Sciences